The ISLAND Study: InSuLa Assessed Needs for Depression
Public ClinicalTrials.gov record NCT02137369. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Testing an Imaging Biomarker for Treatment Stratification in Major Depression
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
While there are many effective options for treating a major depressive episode, there are no clinical markers that predict the likelihood of remission with an initial trial of either an antidepressant medication or psychotherapy. The goal of this study is to test how brain function changes in depress patients treated with cognitive behavioral therapy (CBT) compared to patients treated with a selective serotonin reuptake inhibitor (SSRI, either escitalopram or sertraline), which are FDA approved antidepressants. The study aims to determine if bran scan findings might help physicians to select the most effective antidepressant treatment for an individual patient. Up to 100 male and female outpatients who are between 21-55 years old will be enrolled. Participation in the study will last from 14-26 weeks. Subjects will be randomized to receive either escitalopram (s-CIT) or CBT for 12 weeks. Resting-state positron emission tomography (PET) and BOLD functional magnetic resonance imaging (fMRI) scans will be done before the treatment begins, and again at the end of treatment (week 12). Non-responders to s-cIT or CBT will be crossed over to receive an additional 12 weeks of treatment with the alternative intervention.
Study identification
- NCT ID
- NCT02137369
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 77 participants
Conditions and interventions
Conditions
Interventions
- Selective serotonin re-uptake inhibitor Drug
- Cognitive Behavioral Therapy Behavioral
- Combination treatment (SSRI + CBT) Other
Drug · Behavioral · Other
Eligibility (public fields only)
- Age range
- 18 Years to 60 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 31, 2014
- Primary completion
- Oct 23, 2019
- Completion
- Oct 23, 2019
- Last update posted
- Nov 4, 2020
2014 – 2019
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 12 Executive Park Drive, 3rd floor | Atlanta | Georgia | 30329 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Depression trials
Other public records listing Depression. Sorted by last update posted; newest first. Not a recommendation.
- NCT07796568: Virtual Group Therapy for IBD Patients With Anxiety and Depression Not yet recruiting
- NCT06002204: Studying the Health of Asians to Advance Knowledge, Treatments, and Interventions for Depression Active, not recruiting
- NCT07781228: Supported Online Self-Help for Veterans With Depression in Primary Care Not yet recruiting
- NCT05541406: Efficacy of a Multi-level School Intervention for LGBTQ Youth Active, not recruiting
- NCT06748222: E-Mindfulness Approaches for Living After Breast Cancer Recruiting
- NCT05693571: Engagement in CHildhood-Onset Systemic Lupus Active, not recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02137369, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 4, 2020 · Synced Sep 12, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02137369 live on ClinicalTrials.gov.